SEP - 6 2000

PHILIPS

Philips Medical Systems K002016

510(k) Summary

Company name:	Philips Medical Systems North America Company
Address:	710 Bridgeport Avenue Shelton, CT 06484
Contact person:	P. Altman
Telephone number:	203-926-7031
Prepared:	June 5, 2000
Device name:	Philips Integris Allura systems
Classification name:	Angiographic X-ray system, 21 CFR 892.1600
	Class II (90 IZI)
Common/Usual name:	Angiographic x-ray system
Predicate Device(s):	Philips Integris V5000 and BV5000

Intended use:

- Dedicated vascular and neurovascular imaging applications, including diagnostic and interventional procedures. This includes, e.g., peripheral, cerebral, thoracic, and abdominal angiography, as well as PTCA's, stent placements, embolisations, and thrombolysis.
- Cardiac imaging applications including diagnostics, interventional procedures (such as PTCA, stent placing, atherectomies), pacemaker implantations, and electrophysiology (EP).
- Non-vascular interventions such as drainages and biopsies.

System description:

The Philips Integris Allura is a series of angiographic X-ray systems for vascular, neurovascular, cardiovascular, and also non-vascular procedures. It is available in both a monoplane and biplane configurations. The monoplane Allura features a ceiling suspended C arm stand with a 12" or 15" Image Intensifier. The biplane Allura, has a floor mounted C arm stand combined with a ceiling suspended double C-Arc (LARC). The Floor mounted stand can be configured with a 12" or 15" Image Intensifier, the LARC features a 12" or a 9" Image Intensifier.

Safety / Software Information

An overview of the software description, the design, the summary of hazard analysis results and technical and safety information was included. The systems are designed in compliance with the applicable sections of Title 21 CFR part 1020, UL 187 and 2601, and comply with the ACR/NEMA DICOM digital imaging communication standard.

Philips Medical Systems
North America Company
710 Bridgeport Avenue
P.O. Box 860
Shelton, Connecticut 06484-0917
Tel: (203) 926-7674
Fax: (203) 929-6099

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

SEP - 6 2000

Peter Altman
Director of Regulatory Affairs
Philips Medical Systems
North America Company
710 Bridgeport Avenue
Shelton, CT 06484

Re: K002016
Philips Integris Allura
Dated: June 30, 2000
Received: July 3, 2000
Regulatory class: II
21 CFR 892.1600 and 21 CFR 892.1650
Procode: 90 IZI and 90 JAA

Dear Mr. Altman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Daniel G. Schultz, M.D.
Captain, USPHS
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure(s)

510(k) Number (if known): K002016

Device Name : **Philips Integris Allura**

Indications For Use :

The Philips Integris Allura systems are intended for use in:

- Dedicated vascular and neurovascular imaging applications, including diagnostic and interventional procedures. This includes, e.g., peripheral, cerebral, thoracic, and abdominal angiography, as well as PTCA's, stent placements, embolisations, and thrombolysis.
- Cardiac imaging applications including diagnostics, interventional procedures (such as PTCA, stent placing, atherectomies), pacemaker implantations, and electrophysiology (EP).
- Non-vascular interventions such as drainages and biopsies.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ~~ANOTHER PAGE IF NEEDED~~)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use _____
(Per 21 CFR 801.109

(Optional Format 1-2-96)

(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K002016